mAb-话题@MedSci

#mAb#

1302篇内容 | 2895人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912818, encodeId=50711912818d5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, objectType=article, longId=300936, objectId=cbcd3009360c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcd3009360c, replyNumber=0, likeNumber=64, createdTime=2022-11-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcd3009360c, moduleTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbcd3009360c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912827, encodeId=2c47191282e9f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, objectType=article, longId=301417, objectId=e1c330141efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1c330141efe, replyNumber=0, likeNumber=67, createdTime=2022-09-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1c330141efe, moduleTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1c330141efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912814, encodeId=1b4f1912814a3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, objectType=article, longId=300372, objectId=d6ea3003e273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6ea3003e273, replyNumber=0, likeNumber=88, createdTime=2022-11-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6ea3003e273, moduleTitle=研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6ea3003e273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912880, encodeId=a20a191288066, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点, objectType=article, longId=732815, objectId=31ade3281512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ade3281512, replyNumber=0, likeNumber=78, createdTime=2022-12-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ade3281512, moduleTitle=Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ade3281512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912875, encodeId=2b2019128e5d6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据, objectType=article, longId=731154, objectId=1e2be3115479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2be3115479, replyNumber=0, likeNumber=81, createdTime=2022-09-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2be3115479, moduleTitle=ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e2be3115479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912805, encodeId=b9a01912805f5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, objectType=article, longId=299733, objectId=15e0299e3314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e0299e3314, replyNumber=0, likeNumber=77, createdTime=2022-05-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e0299e3314, moduleTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e0299e3314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912820, encodeId=d9bf19128204f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性, objectType=article, longId=301181, objectId=285330118105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285330118105, replyNumber=0, likeNumber=61, createdTime=2022-06-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285330118105, moduleTitle=JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285330118105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912718, encodeId=b7231912e18f4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, objectType=article, longId=220657, objectId=8c3622065e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3622065e52, replyNumber=0, likeNumber=75, createdTime=2022-03-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3622065e52, moduleTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3622065e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912707, encodeId=67ba1912e07ed, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=中重度未控制哮喘急性加重史对dupilumab临床疗效的影响, objectType=article, longId=219724, objectId=b7fd219e24c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7fd219e24c0, replyNumber=0, likeNumber=87, createdTime=2022-07-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7fd219e24c0, moduleTitle=中重度未控制哮喘急性加重史对dupilumab临床疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7fd219e24c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912725, encodeId=85a21912e25c2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=65, createdTime=2022-04-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912810, encodeId=43351912810b6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, objectType=article, longId=299975, objectId=14d32999e546, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d32999e546, replyNumber=0, likeNumber=76, createdTime=2023-01-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d32999e546, moduleTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14d32999e546)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912700, encodeId=222d1912e0099, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=106, createdTime=2022-06-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912749, encodeId=44731912e49c3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, objectType=article, longId=292586, objectId=8c3b292586ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3b292586ad, replyNumber=0, likeNumber=74, createdTime=2022-03-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3b292586ad, moduleTitle=BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3b292586ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912845, encodeId=eb59191284595, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=百济神州的tislelizumab在中国再次获得批准, objectType=article, longId=724435, objectId=fa20e24435c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa20e24435c4, replyNumber=0, likeNumber=81, createdTime=2022-12-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa20e24435c4, moduleTitle=百济神州的tislelizumab在中国再次获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa20e24435c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912783, encodeId=04a61912e8363, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=134, createdTime=2022-08-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912698, encodeId=d10a19126988f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=52, createdTime=2022-04-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912859, encodeId=165219128594d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=89, createdTime=2022-06-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912737, encodeId=8e1f1912e37b4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=91, createdTime=2022-09-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912710, encodeId=78981912e106b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, objectType=article, longId=220097, objectId=8a2422009e45, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2422009e45, replyNumber=0, likeNumber=65, createdTime=2022-06-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2422009e45, moduleTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a2422009e45)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912829, encodeId=043d19128292c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, objectType=article, longId=301652, objectId=9f863016522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f863016522e, replyNumber=0, likeNumber=68, createdTime=2023-03-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f863016522e, moduleTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f863016522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效

2022-11-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后

2022-09-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

研究性癌症疫苗BNT116联合Libtayo (cemiplimab) 治疗非小细胞肺癌

2022-11-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点

2022-12-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据

2022-09-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性

2022-05-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV：布达鲁（brodalumab）单抗治疗中重度斑块型银屑病的远期疗效和安全性

2022-06-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究

2022-03-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

中重度未控制哮喘急性加重史对dupilumab临床疗效的影响

2022-07-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2022-04-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作

2023-01-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2022-06-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BJH：首次使用抗 VWF 纳米抗体 caplacizumab 治疗妊娠期 iTTP

2022-03-09

snf701207 (审核中...)

前往app查看评论内容

#mAb#

百济神州的tislelizumab在中国再次获得批准

2022-12-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-08-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2022-04-09

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-06-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2022-09-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性

2022-06-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化

2023-03-07

科室
- - 订阅+
  - 更多科室
工具
服务